Coloplast A/S (OTCMKTS:CLPBY) Receives $920.00 Average Price Target from Analysts

Shares of Coloplast A/S (OTCMKTS:CLPBYGet Rating) have been assigned a consensus recommendation of “Hold” from the seven research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $920.00.

Several research firms recently commented on CLPBY. Barclays decreased their price target on shares of Coloplast A/S from 835.00 to 815.00 and set an “underweight” rating on the stock in a research note on Tuesday, January 10th. Sanford C. Bernstein began coverage on shares of Coloplast A/S in a research report on Tuesday. They set a “market perform” rating for the company.

Coloplast A/S Trading Up 1.7 %

CLPBY stock opened at $11.50 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.90 and a current ratio of 1.29. The company’s 50-day simple moving average is $11.92 and its 200 day simple moving average is $11.54. Coloplast A/S has a 52 week low of $9.58 and a 52 week high of $16.00. The company has a market capitalization of $24.84 billion, a PE ratio of 41.07 and a beta of 0.28.

Coloplast A/S Company Profile

(Get Rating)

Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products.

Read More

Analyst Recommendations for Coloplast A/S (OTCMKTS:CLPBY)

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with's FREE daily email newsletter.